RELX Starts China’s First Clinical Study on E-Cigarette Saf

理财鱼小提示：RELX Starts China’s First Clinical Study on E-Cigarette Safety

BEIJING, February 7 (TMTPOST) — Chinese e-cigarette maker RELX’s clinical study on the safety of e-cigarettes has been registered successfully on ChiCTR (China Clinical Trial Registry).

RELX’s research project is said to be the first clinical study to focus on the safety of e-cigarettes in China.

The company also started a clinical study on e-cigarettes earlier in March 2021. The clinical study last year focused on the impact of using e-cigarettes and conventional cigarettes on the biomarkers in human bodies. The study has been completed and the research findings will be released later this year.

Different from the previous study that focused on the metabolism of nicotine, RELX’s new study will focus on key indicators of the clinical study participants’ respiratory function and cardiovascular function to study e-cigarettes’ impact on human bodies.

The study will be conducted by the Sun Yat-sen University-RELX Product Review Lab. The lab is the first lab in China that studies atomization in both clinical and non-clinical projects.

The study will recruit 36 healthy test participants with a smoking habit, according to Professor Zhong Guoping, deputy director of the Sun Yat-sen University-RELX Product Review Lab. Test participants will be put into randomized groups for researchers to observe e-cigarettes’ short-term impact on participants’ respiratory function and cardiovascular function.

Clinical studies are generally conducted for the research and development of new drugs. They are used for assessing the safety and effectiveness of drugs. RELX had conducted a series of research products in physics, chemistry and biology to prove e-cigarettes’ safety.

China has not yet built a comprehensive knowledge and research system on e-cigarettes. The country announced in November 2021 that e-cigarette products fall into the category of tobacco products and are regulated by tobacco law and regulation. China also aims to have stricter control over the production, sales and marketing of e-cigarettes. In December 2021, China’s State Tobacco Monopoly Administration began seeking public opinions on its draft e-cigarette standard guidelines, which specify the nicotine strength limit for e-cigarettes and warns the public about potential health issues that might arise from using e-cigarettes.

>相关《 RELX Starts China’s First Clinical Study on E-Cigarette Saf》内容：

理财鱼小提示：China Top EV Battery Maker CATL May lose One of Most Promising Domestic Clients BEIJING, January 31 (TMTPOST)—One of Tesla’ Chinese rivals with fastest growth was recently said to ditch its key battery partner Contemporary Ampe...【继续阅读】

理财鱼小提示：汤臣倍健：产品力+品牌力双重加持，抢占TEAMCHINA+亚运会双赛道 日前，国家体育总局体育器材装备中心授牌宣布，汤臣倍健（300146）成为TEAMCHINA中国国家队运动食品及营养品供应商，为国家队70余支队伍的运动员供应运动食品、营养品和专业营养备战...【继续阅读】

12月17日，在深圳举行的第五届国际电子烟产业高峰论坛上，RELX悦刻联合创始人、悦刻国际CEO杜冰公布了悦刻海外业务的最新进展。目前，悦刻国际已与众多国际顶尖分销商及家乐福、7-11、Alfamart等全球及本地知名零售连锁达成合作，并在21个国家和地区设立办...【继续阅读】